Loading…
Loading…
ProShares Trust - ProShares Ultra Nasdaq Biotechnology is an exchange traded fund launched and managed by ProShare Advisors LLC. It invests in public equity markets of the United States. It invests through derivatives in stocks of companies operating across health care, pharmaceuticals, biotechnology, drugs manufacturer, diagnostic development and life sciences sectors. It uses derivatives such as swaps to create its portfolio. The fund invests in growth and value stocks of companies across diversified market capitalization. The fund seeks to track 2x the daily performance of the Nasdaq…
Is BIB's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB - Get Free Report)'s stock price crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $84.02 and traded as low as $75.57. ProShares Ultra Nasdaq Biotechnology shares last traded at $77.7580, with a volume of 9,500 shares changing hands. ProShares
ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $74.59 and traded as high as $81.41. ProShares Ultra Nasdaq Biotechnology shares last traded at $80.83, with a volume of 11,789 shares trading
BIB seeks 2× the daily return of the Nasdaq Biotechnology Index, amplifying both gains and losses through leverage. A higher expense ratio reflects leverage costs and management fees; 24 bps difference largely from borrowing and rebate adjustments. Designed for tactical investors, contrasting with MPT's long-term strategic approach assuming market efficiency.
Some of the market's favorite biotech stocks have created immense wealth, as in the recent weight-loss drug stock boom. On May 26, Viking Therapeutics (NASDAQ: VKTX ) was trading around $20.25.
With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.